| Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma R Rampling, G Cruickshank, V Papanastassiou, J Nicoll, D Hadley, ... Gene therapy 7 (10), 859-866, 2000 | 733 | 2000 |
| The potential for efficacy of the modified (ICP 34.5−) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: A proof of principle study V Papanastassiou, R Rampling, M Fraser, R Petty, D Hadley, J Nicoll, ... Gene therapy 9 (6), 398-406, 2002 | 405 | 2002 |
| HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival S Harrow, V Papanastassiou, J Harland, R Mabbs, R Petty, M Fraser, ... Gene therapy 11 (22), 1648-1658, 2004 | 404 | 2004 |
| Comparison of MTT and ATP‐based assays for the measurement of viable cell number RD Petty, LA Sutherland, EM Hunter, IA Cree Journal of bioluminescence and chemiluminescence 10 (1), 29-34, 1995 | 370 | 1995 |
| Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial SJ Dutton, DR Ferry, JM Blazeby, H Abbas, A Dahle-Smith, W Mansoor, ... The lancet oncology 15 (8), 894-904, 2014 | 319 | 2014 |
| Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised … CS Fuchs, K Shitara, M Di Bartolomeo, S Lonardi, SE Al-Batran, ... The Lancet Oncology 20 (3), 420-435, 2019 | 226 | 2019 |
| Common variants at the MHC locus and at chromosome 16q24. 1 predispose to Barrett's esophagus Z Su, LJ Gay, A Strange, C Palles, G Band, DC Whiteman, F Lescai, ... Nature Genetics 44 (10), 1131-1136, 2012 | 206 | 2012 |
| Gene expression profiling in non-small cell lung cancer: from molecular mechanisms to clinical application RD Petty, MC Nicolson, KM Kerr, E Collie-Duguid, GI Murray Clinical Cancer Research 10 (10), 3237-3248, 2004 | 178 | 2004 |
| A deep learning framework for predicting response to therapy in cancer T Sakellaropoulos, K Vougas, S Narang, F Koinis, A Kotsinas, A Polyzos, ... Cell reports 29 (11), 3367-3373. e4, 2019 | 168 | 2019 |
| A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or … E Van Cutsem, YJ Bang, W Mansoor, RD Petty, Y Chao, D Cunningham, ... Annals of Oncology 28 (6), 1316-1324, 2017 | 161 | 2017 |
| Gefitinib and EGFR gene copy number aberrations in esophageal cancer. R Petty, A Dahle-Smith, D Stevenson, A Osborne, D Massie, C Clark, ... | 119 | 2017 |
| Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal … PS Hall, D Swinson, DA Cairns, JS Waters, R Petty, C Allmark, S Ruddock, ... JAMA oncology 7 (6), 869-877, 2021 | 108 | 2021 |
| Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining K Vougas, T Sakellaropoulos, A Kotsinas, GRP Foukas, A Ntargaras, ... Pharmacology & therapeutics 203, 107395, 2019 | 100 | 2019 |
| Increased incidence of visceral metastases in Scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype C Gourley, CO Michie, P Roxburgh, TA Yap, S Harden, J Paul, ... Journal of Clinical Oncology 28 (15), 2505-2511, 2010 | 96 | 2010 |
| Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report AFC Okines, RE Langley, LC Thompson, SP Stenning, L Stevenson, ... Annals of oncology 24 (3), 702-709, 2013 | 85 | 2013 |
| Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation NA Alymani, MD Smith, DJ Williams, RD Petty European Journal of Cancer 46 (5), 869-879, 2010 | 77 | 2010 |
| Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial. PS Hall, D Swinson, JS Waters, J Wadsley, S Falk, R Roy, T Tillett, J Nicoll, ... Journal of Clinical Oncology 37 (15_suppl), 4006-4006, 2019 | 73 | 2019 |
| Tumor transcriptome reveals the predictive and prognostic impact of lysosomal protease inhibitors in non-small-cell lung cancer RD Petty, KM Kerr, GI Murray, MC Nicolson, PH Rooney, D Bissett, ... J Clin Oncol 24 (11), 1729-1744, 2006 | 69 | 2006 |
| A randomized, open-label phase II study of AZD4547 (AZD) versus Paclitaxel (P) in previously treated patients with advanced gastric cancer (AGC) with Fibroblast Growth Factor … YJ Bang, E Van Cutsem, W Mansoor, RD Petty, Y Chao, D Cunningham, ... Journal of Clinical Oncology 33 (15_suppl), 4014-4014, 2015 | 67 | 2015 |
| Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas GH Bain, E Collie-Duguid, GI Murray, FJ Gilbert, A Denison, F McKiddie, ... British journal of cancer 110 (6), 1525-1534, 2014 | 62 | 2014 |
Collie-DuguidUniversity of AberdeenBestätigte E-Mail-Adresse bei abdn.ac.uk
